Vitamin B1 receives considerable attention in discussions about mitochondrial function and intestinal motility. However, my research into the Host Capacity Model has led me to focus increasingly on another overlooked nutrient: vitamin B2, or riboflavin.
One of the central ideas behind this research is that producing butyrate is not the same as being able to use it. Certain intestinal bacteria produce butyrate by fermenting dietary fiber, but butyrate cannot support the intestinal lining simply by being present in the gut. It must enter colonocytes, the cells lining the colon, and be oxidized inside their mitochondria.
The body converts riboflavin into FMN and FAD, two cofactors required for mitochondrial energy metabolism. FAD is essential for short-chain acyl-CoA dehydrogenase, or SCAD, one of the first enzymes involved in butyrate oxidation. After butyrate is activated into butyryl-CoA, SCAD removes electrons from it. Those electrons are transferred through ETF, ETFDH, CoQ and the mitochondrial respiratory chain, where they contribute to ATP production. Several parts of this electron-transfer pathway depend on flavin cofactors derived from vitamin B2.
Vitamin B2 is not the only requirement. Vitamin B5 is needed to produce Coenzyme A, vitamin B3 supports NAD⁺-dependent reactions, and the pathway also depends on CoQ, iron-sulfur clusters, magnesium, mitochondrial integrity and a functioning respiratory chain. However, B2 occupies a critical position at the entrance to butyrate oxidation and in transferring its electrons toward energy production.
This matters because colonocytes do more than burn butyrate for ATP. Their metabolism helps determine which organisms can live near the intestinal surface. When colonocytes oxidize butyrate, their mitochondria consume oxygen. This oxygen consumption helps maintain physiological hypoxia at the epithelial surface and limits the amount of oxygen that diffuses into the intestinal lumen.
If butyrate transport or oxidation declines, colonocytes consume less oxygen. More oxygen can then become available near the intestinal surface, creating an energetic advantage for facultative organisms such as Klebsiella, Escherichia coli, Enterobacter, Citrobacter and Proteus. Unlike strict anaerobic bacteria, these organisms can use oxygen for respiration and generate considerably more energy than organisms restricted to fermentation.
Inflammation provides these bacteria with another respiratory resource: nitrate. Lipopolysaccharide, or LPS, from Gram-negative bacteria activates TLR4 and downstream inflammatory pathways, including NF-κB. This promotes cytokines such as TNF-α and increases inducible nitric-oxide synthase, or iNOS. Under inflammatory and oxidative conditions, nitric oxide can contribute to nitrate formation. Enterobacteriaceae such as Klebsiella and E. coli possess nitrate-reductase systems that allow them to use nitrate as an alternative terminal electron acceptor when oxygen becomes limited. Butyrate-driven PPAR-γ signaling normally helps restrain both oxygen and nitrate availability, reducing this respiratory advantage.
The inflammation creates an additional block: it can reduce the colonocyte’s ability to import butyrate. Butyrate enters epithelial cells largely through transporters such as MCT1, encoded by SLC16A1. Inflammatory cytokines generated downstream of LPS–TLR4–NF-κB signaling, particularly TNF-α and IFN-γ, can reduce MCT1 expression or inhibit MCT1-mediated butyrate uptake. Inflamed intestinal tissue has also been shown to have lower MCT1 expression and reduced butyrate consumption.
This creates a powerful self-reinforcing loop. Gram-negative organisms release LPS, LPS activates TLR4 and NF-κB, and the resulting inflammatory environment reduces butyrate transport into colonocytes. Less butyrate enters the cell, less is oxidized, and mitochondrial oxygen consumption falls. More oxygen reaches the intestinal surface, while iNOS-driven inflammation increases nitrate availability. Oxygen- and nitrate-respiring organisms then gain an even greater energetic advantage, expand further and release more LPS.
The problem is therefore not only insufficient butyrate production. Butyrate may be present in the lumen while inflammation has partially closed the cellular door required for its uptake. The colonocyte becomes deprived of its preferred fuel while unused butyrate remains outside the cell.
This is one reason antibiotics and antimicrobial herbs may produce only temporary improvement. They may reduce Klebsiella, E. coli and other overgrown organisms, but they do not automatically restore MCT1 expression, butyrate oxidation, PPAR-γ signaling, mitochondrial oxygen consumption, barrier integrity, bile-acid regulation, autonomic function or control of inflammatory nitrate production.
If the intestinal environment continues supplying oxygen, nitrate and poorly absorbed substrates, the same organisms—or other organisms with similar respiratory capabilities—may expand again. The antimicrobial reduces the bacterial population without necessarily correcting the host environment that selected for it.
There is another important side to butyrate that is often overlooked. Butyrate is not only a fuel; it is also an epigenetic signaling molecule. When differentiated colonocytes oxidize butyrate normally, much of it is consumed in their mitochondria. But when butyrate enters a cell that cannot oxidize it efficiently, more may remain available to enter the nucleus and inhibit histone deacetylases, or HDACs.
HDACs are enzymes that remove acetyl groups from histone proteins around which DNA is wrapped. Removing these groups generally makes chromatin more compact and changes which genes are accessible for transcription. By inhibiting HDACs, unoxidized butyrate increases histone acetylation and can alter the expression of genes controlling inflammation, differentiation, apoptosis and the cell cycle. In cells that oxidize little butyrate, it therefore acts less like mitochondrial fuel and more like a powerful regulator of gene expression.
This becomes especially important for the stem and progenitor cells located deep within the colonic crypts. These cells must proliferate continuously to replace the intestinal epithelium. Under normal conditions, mature colonocytes positioned above them metabolize much of the butyrate before it can reach the crypt base. In this way, colonocyte oxidation acts as a metabolic barrier protecting the stem-cell compartment.
Research has shown that when butyrate reaches intestinal stem and progenitor cells at sufficient concentrations, it can suppress their proliferation through a mechanism involving the transcription factor FOXO3. When the mucosa is injured or the protective layer of differentiated colonocytes is disrupted, butyrate can gain greater access to the crypt and delay epithelial regeneration.
This helps explain why simply adding more butyrate may not always correct a damaged gut. In a metabolically healthy colon, butyrate supports colonocyte energy production, oxygen consumption and barrier function. In a host with impaired transport, reduced oxidation or significant mucosal injury, additional butyrate may remain unoxidized, produce stronger HDAC-mediated effects and potentially reach proliferating cells that are normally protected from it.
This does not mean butyrate is inherently harmful. It means that its effects depend on location, concentration, epithelial integrity and the host’s capacity to transport and oxidize it.
When I work with clients experiencing recurring SIBO, persistent dysbiosis, slow transit, elevated Klebsiella or other nitrate-respiring organisms, I do not focus only on which bacteria are elevated. I investigate why the intestinal environment may be supporting them. This includes butyrate production versus utilization, vitamin B2 and flavin-dependent metabolism, MCT1 transport, SCAD, ETF, ETFDH, CoQ, PPAR-γ signaling, oxygen and nitrate availability, inflammatory signaling, hydrogen-sulfide burden, bile-acid metabolism, epithelial integrity, autonomic regulation and transit time.
In selected clients, I have observed improvements in intestinal transit and gastrointestinal function when riboflavin-dependent metabolism was addressed as part of a broader mitochondrial and epithelial strategy. I do not view B2 as a direct antimicrobial or laxative. I view it as one component of the machinery that allows colonocytes to import and oxidize butyrate, consume oxygen, produce energy and maintain an intestinal environment that is less favorable to respiratory pathobionts.
This is the foundation of my Host Capacity Model. Persistent dysbiosis may continue not simply because certain bacteria are present, but because the host has lost part of its capacity to regulate the environment in which those bacteria live.
You can read more about my research, clinical observations and the Host Capacity Model through BiomeLogic.